SCHEMBL7123357

SCHEMBL7123357

CC([O])Sc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
MMP2 P08253 1/20 0.50
MMP8 P22894 1/20 0.50
MMP14 P50281 1/20 0.50
TSHR P16473 1/20 0.49
MMP1 P03956 1/20 0.46
HPGD P15428 3/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
LMNA P02545 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
THRB P10828 2/20 0.40
PLA2G1B P04054 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216701 0.80 HSD17B10 (0.50) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL5983975 0.78 HPGD (0.46) HPGDLMNANPSR1SMN1; SMN2L3MBTL1
SCHEMBL315823 0.78 HSD17B10 (0.48) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL7297677 0.76 MAPK1 (0.46) TSHRCYP3A4LMNANPSR1SMN1; SMN2
SCHEMBL15241839 0.76 CYP2C9 (0.47) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL9602267 0.76 TSHR (0.49) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL11292783 0.76 HSD17B10 (0.47) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL95521 0.75 LMNA (0.42) HSD17B10HPGDLMNASMN1; SMN2L3MBTL1
SCHEMBL7398296 0.74 CYP2C9 (0.66) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL7245397 0.73 ADRB2 (0.46) HSD17B10CYP2C9CYP2C19MMP2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030008914-A1 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS MILLENNIUM PHARMACEUTICALS, INC. 2003-01-09 US disclosed
EP-1123095-A1 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS Millennium Pharmaceuticals, Inc. (US) 2001-08-16 EP disclosed
WO-2000023071-A9 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS LEUKOSITE INC (US) 2000-09-14 WO disclosed
WO-2000023071-A1 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS LEUKOSITE, INC. (US) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008914-A1 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS ALOX5, ALOX5AP, ALOX15 HSD17B10 823/4885CYP2C9 1406/4885CYP2C19 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.